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Key messages
What is already known about this subject?
 ► In interstitial lung disease, there is a lack of 
validated biomarkers for disease staging, 
prediction of disease progression and drug 
responses, which impairs tailored patient 
management.
What does this study add?
 ► Our preclinical data suggest that targeted 
nuclear imaging of pathophysiological key 
players allows the visualisation of specific 
molecular processes of interstitial lung disease.
How might this impact on clinical practice or 
future developments?
 ► If transferred into clinics, where medical 
imaging is already part of the routine clinical 
work-up, the added information derived from 
specific diagnostic tools could represent the first 
step towards precision medicine in interstitial 
lung disease.
ABsTrACT
Objective to evaluate integrin αvβ3 (alpha-v-beta-3)-
targeted and somatostatin receptor 2 (SStr2)-targeted 
nuclear imaging for the visualisation of interstitial lung 
disease (ILd).
Methods the pulmonary expression of integrin αvβ3 
and SStr2 was analysed in patients with different forms 
of ILd as well as in bleomycin (BLM)-treated mice and 
respective controls using immunohistochemistry. Single 
photon emission Ct/Ct (SpECt/Ct) was performed on 
days 3, 7 and 14 after BLM instillation using the integrin 
αvβ3-targeting 177Lu-dotA-rGd and the SStr2-
targeting 177Lu-dotA-noC radiotracer. the specific 
pulmonary accumulation of the radiotracers over time 
was assessed by in vivo and ex vivo SpECt/Ct scans and 
by biodistribution studies.
results Expression of integrin αvβ3 and SStr2 was 
substantially increased in human ILd regardless of the 
subtype. Similarly, in lungs of BLM-challenged mice, 
but not of controls, both imaging targets were stage-
specifically overexpressed. While integrin αvβ3 was most 
abundantly upregulated on day 7, the inflammatory 
stage of BLM-induced lung fibrosis, SStr2 expression 
peaked on day 14, the established fibrotic stage. In 
agreement with the findings on tissue level, targeted 
nuclear imaging using SpECt/Ct specifically detected 
both imaging targets ex vivo and in vivo, and thus 
visualised different stages of experimental ILd.
Conclusion our preclinical proof-of-concept study 
suggests that specific visualisation of molecular 
processes in ILd by targeted nuclear imaging is feasible. 
If transferred into clinics, where imaging is considered 
an integral part of patients’ management, the additional 
information derived from specific imaging tools could 
represent a first step towards precision medicine in ILd.
InTrOduCTIOn
Interstitial lung disease (ILD) is an umbrella term 
for a group of heterogeneous chronic parenchymal 
lung disorders with different aetiologies. The most 
prevalent subtypes include idiopathic pulmonary 
fibrosis (IPF) and ILD in the context of connective 
tissue diseases (CTD), particularly in association 
with systemic sclerosis (SSc).1–3 Pulmonary fibrosis 
is the common end stage of ILD.4 Histologically, the 
most common pattern of SSc-ILD is non-specific 
interstitial pneumonia (NSIP), whereas in IPF it is 
usual interstitial pneumonia (UIP).2 4 In contrast to 
IPF, in SSc-ILD, this histological classification is not 
considered a reliable tool for outcome prediction.2 5 
However, the differences in cellularity, cell types 
and degree of lung remodelling in NSIP versus UIP 
point to differences in the underlying pathophysi-
ology.2 4
Currently, in ILD, no validated biomarkers 
for disease staging, prediction of disease progres-
sion and drug responses exist.6–8 Given the highly 
heterogeneous nature of ILD, this largely leaves 
patient management at a trial-and-error stage, 
which stands in sharp contrast to the concept of 
precision medicine.8 9
To address this unmet clinical need, we evaluated 
whether nuclear imaging as a specific (‘targeted’) and 
functional imaging modality could provide molec-
ular information on the underlying pathophysi-
ology10 that could be used for substratification and 
tailored decision-making in ILD. Nuclear imaging 
methodologies include single photon emission CT 
(SPECT) and positron emission tomography (PET), 
which use radiolabelled, target-specific, molecular 
probes, that is, radiotracers for the real-time visu-
alisation of pathophysiological processes.10 For 
a proof-of-concept study showing that targeted 
nuclear imaging is feasible and has the potential for 
clinical application in ILD, we have selected two 
different molecules involved in the pathophysiology 
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of ILD, that is, integrin alpha-v-beta-3 (αvβ3) and somatostatin 
receptor 2 (SSTR2), for which validated radiotracers are already 
available with good potential for short-term transferability into 
clinical application.11 12 Compared with the current gold-stan-
dard diagnostic imaging methodologies, including high-resolu-
tion CT (HRCT) or 18F-fluorodesoxyglucose (FDG)-PET/CT, 
integrin αvβ3-targeted and SSTR2-targeted nuclear imaging may 
have important advantages for the evaluation of patients with 
ILD. Although HRCT and 18F-FDG-PET/CT are sensitive tools 
for the diagnosis of ILD, they are unspecific and cannot be used 
for the molecular subtyping of patients. Since they solely rely on 
the detection of changes in tissue morphology or in metabolic 
activity, respectively, they do not allow the discrimination of 
different pathophysiological stages of ILD, that is, inflammation, 
active fibrotic remodelling or established fibrosis,13 14 which is 
paramount for informed treatment decisions and monitoring of 
therapeutic responses.
Alpha v integrins are key molecules in the pathogenesis of 
fibrosis in multiple organs due to their ability to activate matrix-
bound latent transforming growth factor beta (TGF-β), the proto-
typical profibrotic cytokine in tissue fibrosis.15 16 Of particular 
importance in this regard is integrin αvβ3, which by activating 
TGF-β establishes an autocrine signalling loop in fibroblasts, 
thus driving myofibroblast differentiation.16 17 Targeted imaging 
of integrin αvβ3 can be realised with arginine-glycine-aspartic 
acid (RGD) tripeptide-based radiotracers, which have already 
been validated (pre-)clinically.11 18 19
SSTR2 is a G-protein-coupled receptor which is expressed on 
various cellular key players of lung remodelling, for example, 
epithelial cells, inflammatory cells20 21 and potentially fibro-
blasts.22 SSTR2 can be targeted with a series of peptides, that 
is, somatostatin analogues, which are already part of the routine 
management of neuroendocrine tumours.12 23 Radiolabelled 
somatostatin analogues have recently been proposed for the 
visualisation of fibrotic changes in experimental24 25 and human 
ILD.26–29
Herein, we evaluated the potential of molecular imaging of 
integrin αvβ3 and SSTR2 for the targeted visualisation of patho-
physiological stages of ILD using the well-defined model of bleo-
mycin (BLM)-induced lung fibrosis.
MeTHOds
A detailed description of the materials and methods, including 
information on patient characteristics, is provided in the online 
supplementary information.
resulTs
expression of integrin αvβ3 and ssTr2 is increased in 
different types of Ild
To assess whether the expression of our molecular imaging 
targets is increased in human ILD, we performed immunohisto-
chemistry for the β3 chain of integrin αvβ3 and SSTR2 on lung 
sections from patients with different types of ILD, including IPF 
and SSc-ILD, and other types of CTD-ILD (online supplemen-
tary table S1). Tissue specimens were obtained in the context 
of lung transplantation. The histopathological analysis revealed 
severely damaged lung architecture with massive accumulation 
of inflammatory infiltrates and extensive interstitial collagen 
deposition as assessed by H&E and CD45 or Picrosirius red 
and alpha-smooth muscle actin (αSMA) staining, respectively, 
which was consistent with end-stage ILD (figure 1A, online 
supplementary figure S1). In these highly inflamed and fibrotic 
lungs, expression of integrin αvβ3 and SSTR2 was significantly 
increased (~3-fold to 4-fold, p<0.05) compared with lungs from 
healthy subjects (figure 1A–C). Notably, this increase in expres-
sion was independent of the underlying aetiological subtype of 
ILD (figure 1A–C) and of other clinical characteristics (online 
supplementary figures S2 and S3). However, when comparing 
the expression of integrin αvβ3 and SSTR2 with respect to the 
histological subtypes of ILD, UIP and NSIP, we found a signifi-
cantly higher expression of SSTR2 in the lungs with UIP pattern 
compared with those with NSIP pattern (p<0.01). In contrast, 
the expression of integrin αvβ3 did not differ between both 
histological subtypes (figure 1D,E).
expression of integrin αvβ3 and ssTr2 reflects different 
disease stages of experimental Ild
Given these promising results, we next assessed whether inte-
grin αvβ3 and SSTR2 could also serve as surrogate markers for 
different pathophysiological stages in ILD. Therefore, we exam-
ined the time course of the pulmonary expression of integrin 
αvβ3 and SSTR2 in a representative mouse model of human 
ILD, the model of BLM-induced lung fibrosis.
A single intratracheal instillation of BLM (4 U/kg of body 
weight) in mice induced progressive lung remodelling with 
inflammation leading to established pulmonary fibrosis already 
14 days after the BLM administration as assessed by tissue 
analysis (figure 2A,B) and CT scanning (online supplementary 
figure S4). Already on day 3, lungs from BLM-treated mice 
versus saline controls showed the presence of perivascular and 
peribronchial cellular infiltrates (figure 2A, H&E staining), 
which mainly consisted of CD45+ leucocytes (figure 2A, CD45 
staining). In contrast, only limited fibrous thickening of the alve-
olar and bronchial walls (figure 2A, Picrosirius red staining) with 
no increase in αSMA expression (figure 2A, αSMA staining) was 
observed. With disease progression, the number of inflamma-
tory infiltrates increased in BLM-treated lungs, peaked on day 7, 
and subsided thereafter (figure 2A, H&E and CD45 staining). In 
contrast, pulmonary fibrosis, characterised by extensive intersti-
tial collagen deposition and increase of αSMA expression in the 
lung interstitium, reached its maximum on day 14 (figure 2A, 
Picrosirius red and αSMA staining). Although the progressing 
damage of lung architecture could also be depicted on CT 
(online supplementary figure S4), these morphological changes 
could not relay information on the underlying pathophysiology, 
that is, inflammation or fibrosis.
Notably, compared with saline-treated controls, the lungs of 
BLM-challenged mice showed significantly increased expression 
of integrin αvβ3 and SSTR2 at all time points. Interestingly, the 
expression of integrin αvβ3 was most abundant on day 7 and 
thus in the inflammatory stage of BLM-induced lung fibrosis, 
where inflammation is more dominant than fibrosis, with a 
median increase of 3.7(Q1, Q3=2.9, 4.5)-fold (p<0.001) compared 
with control lungs (figure 2A–C). Although integrin expression 
decreased on day 14, it remained significantly upregulated in 
the lungs of BLM-treated mice (median(Q1, Q3)=2.4(2.0, 4.2)-fold) 
(p<0.01). In contrast, the expression of SSTR2 gradually 
increased with the degree of lung remodelling and peaked on 
day 14, and thus in the fibrotic stage of this animal model, with a 
median of 3.8(Q1, Q3=2.2, 4.3)-fold (p<0.01) increase compared with 
the lungs from saline-treated controls (figure 2A–D).
Given the rather conflicting reports of the pulmonary expres-
sion of integrin αvβ3 and SSTR2 in the literature,20 24 we addi-
tionally analysed the cellular expression profiles of both targets 
in lung sections of BLM-treated mice and respective controls. 
Using immunofluorescent and/or immunohistochemical double 
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Figure 1 Expression of integrin alpha-v-beta-3 (αvβ3) and SSTR2 is increased in different types of human ILD. (A) Representative images of 
lung sections from healthy controls (n=26) and patients with IPF (n=39), SSc-ILD (n=11) and CTD-ILD (n=9) that were stained with H&E (first 
panel) and Picrosirius red (collagen=red, second panel), as well as stained for integrin αvβ3 (brown, third panel) and SSTR2 (brown, fourth panel). 
Representative images at 100× magnification (scale bars: 100 µm) and at higher magnification (400×, scale bars: 20 µm) are displayed. (B) 
Semiquantification of integrin αvβ3 expression by automatic image analysis. (C) Semiquantification of SSTR2 expression by automatic image analysis. 
(D) Analysis of integrin αvβ3 expression depending on the histological subtypes UIP and NSIP. (E) Analysis of SSTR2 expression depending on the 
histological subtypes UIP and NSIP. For B and C, data are displayed as box plots showing medians with min/max values. For D and E, individual data 
points for each patient and type of ILD are plotted with the black line indicating the grand median. For statistical analysis, Kruskal-Wallis test with 
Dunn’s multiple correction or Mann-Whitney U test was applied (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). CTD, connective tissue disease; 
HC, healthy control; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; SSc, systemic sclerosis; 
SSTR2, somatostatin receptor 2; UIP, usual interstitial pneumonia.
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Figure 2 Integrin alpha-v-beta-3 (αvβ3) and SSTR2 are stage-specifically increased in BLM-induced lung fibrosis. (A) Representative images of 
lung sections from saline controls and BLM-treated mice on days 3, 7 and 14 stained with H&E (first panel), pan-leucocyte marker CD45 (brown, 
second panel), Picrosirius red (collagen fibres=red, third panel), myofibroblast marker (αSMA, pink, fourth panel), as well as stained for integrin 
β3 (brown, fifth panel) and SSTR2 (brown, sixth panel). (B) Schematic illustration of the time course of BLM-induced lung fibrosis with the 
inflammatory stage (days 3–7 preceding the fibrotic stage (day 14). (C) Semiquantification of integrin β3 expression by automatic image analysis. (D) 
Semiquantification of SSTR2 expression by automatic image analysis. For A, representative pictures at 100× magnification (scale bars: 100 µm) and 
at higher magnification (400×, scale bars: 20 µm) are shown. For C and D, data are presented as medians±IQR. For statistical analysis, Mann-Whitney 
U test was applied (*p<0.05, **p<0.01, ***p<0.001). For all experiments: n=6 for saline-treated controls and n=9–10 for BLM-treated mice. BLM, 
bleomycin; SSTR2, somatostatin receptor 2.
stainings with cell type-specific markers, we found both integrin 
αvβ3 and SSTR2 expressed on a broad range of inflammatory 
cell types, including leucocytes (CD45+, figure 3A,B), macro-
phages (F4/80+, figure 3C,D) and T cells (CD3+, figure 3E,F). 
Substantial expression of SSTR2 was found on pulmonary bron-
chial and alveolar epithelial cells (E-cadherin+), whereas expres-
sion of integrin αvβ3 was only rarely observed on epithelial cells 
in BLM-treated lungs and was absent on the epithelial cells in the 
lungs from the control mice (figure 3G,H). While integrin αvβ3 
was strongly expressed on the pulmonary vasculature, including 
endothelial cells (von Willebrand factor (vWF)+, figure 3I), 
SSTR2 expression was not detected on vWF+ endothelial cells 
despite being expressed in vascular structures (figure 3J).
The most interesting difference in the pulmonary expres-
sion pattern between integrin αvβ3 and SSTR2 was the pres-
ence of integrin αvβ3, but absence of SSTR2 on myofibroblasts 
(αSMA+, figure 4A,B). The latter observation was in contrast 
to previous positive reports.20 24 To confirm that the different 
expression of integrin αvβ3 and SSTR2 on murine lung fibro-
blasts also applies to human cells, we additionally analysed 
the mRNA and protein expression of both targets in normal 
human lung fibroblasts (NHLF) at basal conditions and after 
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Figure 3 Cellular expression profiles of integrin alpha-v-beta-3 (αvβ3) and SSTR2 in the lungs of BLM-treated mice and saline-treated controls. 
(A) Immunofluorescent (IF) double staining of integrin β3 (red) and CD45 (green, leucocyte marker). (B) Immunohistochemical (IHC) double staining 
and sequential single stainings of SSTR2 (brown) and CD45 (green). (C) IF double staining of integrin β3 (red) and F4/80 (green, murine macrophage 
marker). (D) IHC double staining and sequential single stainings of SSTR2 (brown) and F4/80 (green). (E) IF double staining of integrin β3 (red) 
and CD3 (green, T cell marker). (F) IHC double staining and sequential single staining of SSTR2 (brown) and CD3 (green). (G) IF double staining of 
integrin β3 (red) and E-cadherin (E-cad, green, epithelial cell marker). (H) IHC double staining and sequential single staining of SSTR2 (brown) and 
E-cadherin (E-cad, green). (I) IHC double staining and sequential single staining of integrin β3 (brown) and vWF (purple, endothelial cell marker). (J) 
IHC double staining and sequential single staining of SSTR2 (brown) and vWF (purple). For all experiments, representative images (scale bars 10 µm 
for IF stainings (630× magnification) and 20 µm for IHC stainings (400× magnification) from three mice each are shown. BLM, bleomycin; SSTR2, 
somatostatin receptor 2; vWF, von Willebrand factor.
 o
n
 28 Novem
ber 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214322 on 17 Novem
ber 2018. Downloaded from
 
6 Schniering J, et al. Ann Rheum Dis 2018;0:1–10. doi:10.1136/annrheumdis-2018-214322
Basic and translational research
Figure 4 Integrin alpha-v-beta-3 (αvβ3) but not SSTR2 is expressed on murine and human (myo)fibroblasts. (A) Immunofluorescent (IF) double 
staining of integrin β3 (red) and αSMA (green, myofibroblast marker). (B) Immunohistochemical (IHC) double staining and sequential single 
stainings of SSTR2 (brown) and αSMA (alpha-smooth muscle actin) (pink). (C) Representative western blot for integrin β3 and αSMA expression in 
unstimulated NHLFs and on TGF-β stimulation (10 ng/mL) for 24 hours, 48 hours and 72 hours (10 µg of protein/lane). (D) Representative western 
blot for SSTR2 expression in unstimulated NHLFs and on TGF-β stimulation (10 ng/mL) for 24 hours, 48 hours and 72 hours (50 µg of protein/lane). 
Whole brain protein lysate served as positive control (20 µg of protein/lane). Arrow points to the expected SSTR2 protein band at ~60 kDa. (E, F) Fold 
change of (E) mRNA expression of integrin β3 (ITGB3) normalised to RPLP0 and (F) protein expression of integrin β3 normalised to glycerinaldehyd-
3-phosphat-dehydrogenase (GAPDH) at basal conditions and after stimulation with TGF-β. (G, H) Fold change of (G) mRNA expression of αSMA 
(ACTA2) normalised to RPLP0 and (H) protein expression of αSMA normalised to GAPDH at basal conditions and after stimulation with TGF-β. (I) 
mRNA expression analysis of SSTR2 showing the absence of SSTR2 expression in NHLFs at basal conditions and after stimulation with TGF-β. As a 
positive control served total brain RNA. For A and B, representative images (scale bars 10 µm for IF stainings (630× magnification) and 20 µm for IHC 
stainings (400× magnification)) from three mice each are shown. For E–I, data were expressed as mean±SD. For statistical analysis, one-way analysis 
of variance with Turkey’s post-hoc test was performed (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). BLM, bleomycin; NHLFs, normal human 
lung fibroblasts; SSTR2, somatostatin receptor 2; TGF-β, transforming growth factor beta.
differentiation into myofibroblasts on stimulation with TGF-β. 
Integrin αvβ3 was constitutively expressed in NHLF and showed 
a time-dependent increase after TGF-β-induced fibroblast acti-
vation at the mRNA and protein levels (figure 4C,E,F), similar to 
ACTA2/αSMA (figure 4C,G,H). In contrast, mRNA and protein 
levels of SSTR2 were not detectable in NHLF neither at basal 
conditions nor after stimulation with TGF-β (figure 4D/I and 
online supplementary figure S5), which so far has been a major 
matter of debate.20 24 Thus, we could confirm similar expression 
patterns of our imaging targets on both murine and human lung 
fibroblasts.
detection of integrin αvβ3 with 177lu-dOTA-rGd-sPeCT/CT 
visualises inflammatory stages of lung fibrosis
Having confirmed integrin αvβ3 and SSTR2 as potential 
imaging targets in ILD, targeted nuclear imaging was performed 
to confirm their suitability as surrogate imaging markers for 
 o
n
 28 Novem
ber 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214322 on 17 Novem
ber 2018. Downloaded from
 
7Schniering J, et al. Ann Rheum Dis 2018;0:1–10. doi:10.1136/annrheumdis-2018-214322
Basic and translational research
pathophysiological processes in ILD. Since in the preclinical 
setting SPECT/CT often outperforms PET/CT with respect to 
image quality and resolution, SPECT/CT scans using the inte-
grin αvβ3-targeting 177Lu-DOTA-RGDand the SSTR2-targeting 
177Lu-DOTA-NOC were performed on days 3, 7 and 14 after the 
BLM instillation.
Consistent with the expression changes of integrin αvβ3 
observed on tissue level, biodistribution studies (figure 5A and 
online supplementary tables S4 and S5) and ex vivo SPECT/
CT scans (figure 5B) performed 2 hours postinjection (p.i.) 
of 177Lu-DOTA-RGD revealed a significant increase of tracer 
uptake and signal intensity in the lungs of BLM-treated mice 
versus control mice at all time points. The strongest tracer accu-
mulation in BLM-treated lungs was observed on day 7 with a 
mean lung uptake of 0.65%±0.13% injected activity per lung (% 
IA/lung) compared with 0.19%±0.04% IA/lung in the respective 
control lungs (p<0.01). Specificity of the pulmonary accumula-
tion of 177Lu-DOTA-RGD was validated by receptor blockade 
with an unlabelled RGD peptide, which significantly reduced 
the pulmonary radioactivity amounts of 177Lu-DOTA-RGD in 
BLM-treated mice to the levels detected in control animals. This 
was quantified by biodistribution studies and visualised by ex 
vivo SPECT/CT scans. The in vivo SPECT/CT imaging closely 
mirrored our ex vivo imaging results with the highest signal 
intensity observed on day 7 (figure 5C), the inflammation-dom-
inant stage of BLM-induced lung fibrosis.
detection of ssTr2 with 177lu-dOTA-nOC-sPeCT/CT visualises 
established lung fibrosis
BLM-treated mice showed a steady increase of pulmonary accu-
mulation of 177Lu-DOTA-NOC as compared with saline-treated 
controls in biodistribution studies and ex vivo SPECT/CT scans 
that were performed 2 hours p.i. of 177Lu-DOTA-NOC. This 
was in line with the expression changes of SSTR2 at the tissue 
level (figure 5D,E). The highest lung accumulation in BLM-chal-
lenged mice, and hence the highest imaging signal intensity, was 
observed on day 14, the peak of pulmonary fibrosis, with an 
accumulation of 1.62%±0.32% IA/lung vs 0.66%±0.09% IA/
lung in control lungs (p<0.0001). Due to already high basal 
pulmonary tracer accumulation observed in control animals, 
diseased lungs could only be reliably distinguished on day 14 
(figure 5E and online supplementary tables S6 and S7). In vivo 
imaging mirrored the ex vivo findings and allowed the distinc-
tion of BLM-treated lungs from healthy lungs on day 14, the 
time point of established fibrosis, yet not at earlier, more inflam-
matory time points (figure 5F). The specificity of the pulmo-
nary uptake of 177Lu-DOTA-NOC, and thus of our imaging 
results, was confirmed by receptor blockade with unlabelled 
DOTA-NOC, which almost completely prevented the pulmo-
nary accumulation of the radiotracer in BLM-treated mice 
(figure 5D,E).
dIsCussIOn
This study addressed a major unmet need in ILD, the lack of 
pathophysiologically relevant biomarkers allowing disease 
staging. Our comprehensive approach integrating tissue-de-
rived human and murine ex vivo and in vivo (imaging) data 
extends previously published nuclear imaging studies in ILD, 
where molecular analyses on tissue levels have largely not been 
performed.26–29
One of the first key findings of our study was that the expres-
sion of our imaging targets did not differ between different aeti-
ologies of ILD comprising IPF and CTD-associated ILD. With 
pulmonary fibrosis as the common end stage, increasing data 
support the importance of dysregulated wound-healing mecha-
nisms for both entities.2 30 Furthermore, in contrast to previous 
assumptions regarding the non-inflammatory pathogenesis of 
IPF,5 31 lately, the potential pathogenic role of immune cells in the 
development and progression of IPF has been re-evaluated.32 33 
Thus, a molecular-based rather than a clinical/histological-driven 
classification as the basis for substratification of patients with 
ILD might open novel perspectives.
Consistent with the expression of integrin αvβ3 on (activated) 
fibroblasts in addition to immune cells, we identified integrin 
αvβ3 as a valuable diagnostic tool for inflammation-dominant 
fibrotic stages of ILD and demonstrated that molecular-targeted 
SPECT/CT imaging using a radiolabelled RGD peptide can act 
as a surrogate marker for integrin αvβ3 expression. However, 
given the central roles of integrins in the pathogenesis of ILD, 
other integrins might also be attractive as imaging targets.11 34 
Of particular interest is, for example, integrin αvβ6, which is 
expressed on epithelial cells, and overexpressed in wound healing 
and IPF.35–38 Preclinical imaging studies in BLM-induced lung 
fibrosis confirmed its potential,34 and results from phase I 
clinical trials on imaging in IPF are soon to be awaited ( www. 
clinicaltrials. gov; NCT03183570 and NCT02052297). Besides 
showing great promise as novel diagnostic tools, integrins repre-
sent potential therapeutic targets in ILD. Evidence from preclin-
ical models of organ fibrosis demonstrated beneficial antifibrotic 
effects for the inhibition of integrin signalling.15 16 37 38 In 
oncology, numerous selective integrin inhibitors are currently 
being tested in clinical trials,39–41 since many tumours overex-
press integrin αvβ3, αvβ5 and/or αvβ6.42 Given the promising 
data from preclinical fibrosis models, these approaches could be 
easily applied for studies in ILD.
In contrast to integrin αvβ3, our data suggest that SSTR2 
may serve as a diagnostic tool for established lung fibrosis and 
thus ILD severity. Targeted SPECT/CT using the radiolabelled 
somatostatin analogue DOTA-NOC revealed a steady increase in 
signal intensity over time mirroring the degree of tissue remod-
elling, thereby reaching its peak on day 14, the time point of 
established fibrosis. This is also in line with the increased expres-
sion of SSTR2 in patients with ILD with UIP pattern, where lung 
remodelling is more severe than in the NSIP subtype and where 
epithelial cells are supposed to be the central drivers of pulmo-
nary fibrosis.30 Further support comes from preliminary nuclear 
imaging studies targeting SSTR2 with different radiolabelled 
somatostatin analogues in patients with ILD, which showed 
lower signal intensity in patients with NSIP/SSc-ILD compared 
with patients with IPF/UIP.27–29 Like integrin αvβ3, SSTR2 has 
diagnostic and therapeutic potential. Several preclinical studies 
using different somatostatin analogues showed beneficial effects 
on organ fibrosis.24 43 44 Although increasing data suggest SSTR2 
for imaging and possibly treatment of ILD, it should be pointed 
out that the precise pathophysiological role of SSTR2 in ILD has 
yet to be elucidated. Of note, SSTR-targeted (radio)pharmaceu-
ticals are not specific for SSTR2, but also bind to other soma-
tostatin receptors with similar affinity, including SSTR3 and 
SSTR5.20 45 46 Herein, we demonstrated on several experimental 
levels that neither murine nor human lung fibroblasts express 
SSTR2. In previous studies which had reported on the SSTR2 
expression on fibroblasts, fibroblasts from other sites of origin 
(eg, skin, retro-orbital space or liver)47–49 and/or from embryonic 
stage were assessed.50 This, and the fact that SSTR2 is expressed 
in two protein variants, generated by alternative splicing,51 
might well account for the observed differences. Consequently, 
in (experimental) ILD, it seems likely that both radiotracer 
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Figure 5 Integrin alpha-v-beta-3 (αvβ3) and SSTR2 can serve as surrogate imaging biomarkers for stage-specific detection of experimental ILD. 
(A) Ex vivo lung uptake of 177Lu-DOTA-RGD (2 hours p.i.) shown as percentage of injected activity per lung (% IA/lung) in lungs from saline-treated 
controls and BLM-treated mice with and without receptor blockade on days 3, 7 and 14 after the BLM instillation. (B) Ex vivo SPECT/CT scans of lungs 
from saline-treated controls and BLM-treated mice with and without receptor blockade on days 3, 7 and 14 that were collected 2 hours after injection 
of 177Lu-DOTA-RGD. Ex vivo scans are shown as maximum intensity projections. (C) Representative images of in vivo SPECT/CT scans of saline 
controls and BLM-treated mice on days 3, 7 and 14 performed 2 hours after injection of 177Lu-DOTA-RGD. Transaxial projections of the lung windows 
are shown. (D) Ex vivo lung uptake of 177Lu-DOTA-NOC (2 hours p.i.) shown as percentage of injected activity per lung (% IA/lung) in lungs from 
saline-treated controls and BLM-treated mice with and without receptor blockade on days 3, 7 and 14 after the BLM instillation. (E) Ex vivo SPECT/
CT scans of lungs from saline-treated controls and BLM-treated mice with and without receptor blockade on days 3, 7 and 14 that were collected 2 
hours after injection of 177Lu-DOTA-NOC. Ex vivo scans are shown as maximum intensity projections. (F) Representative images of in vivo SPECT/CT 
scans of saline controls and BLM-treated mice on days 3, 7 and 14 performed 2 hours after injection of 177Lu-DOTA-NOC. Transaxial projections of the 
lung windows are shown. For A and D, data are presented as mean±SD. For statistical analysis, one-way analysis of variance with Turkey’s multiple 
correction was applied (**p<0.01, ***p<0.001, ****p<0.0001, vs saline; ##p<0.01, ####p<0.0001, vs BLM). For biodistribution and ex vivo SPECT/
CT scans: n=3–7 for saline controls, n=5–8 for BLM-treated mice, and n=3–6 for BLM-treated mice receiving receptor blockade. BLM, bleomycin; ILD, 
interstitial lung disease; p.i.; postinjection; SPECT, single photon emission CT; SSTR2, somatostatin receptor 2.
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uptake and antifibrotic effects of SSTR analogues can largely 
be attributed to inflammation and epithelial cell damage.24 27 
However, further studies are needed to assess whether pulmo-
nary fibroblasts express SSTR3 and SSTR5 and might therefore 
be directly targeted by somatostatin analogues.
Additional profibrotic molecules which could be of interest for 
targeted nuclear imaging include extracellular matrix proteins, 
for example, collagens, fibronectin or fibroblast activation 
protein.3 52 However, in contrast to our selected imaging targets, 
radiotracers for these molecules have so far only been validated 
in animal models53 54 or in human non-ILD conditions.55–57 
Furthermore, imaging tools that exclusively detect fibrotic 
changes will probably not reflect pathophysiological changes 
caused by immune and/or epithelial cells and consequently may 
provide a less complete picture of the overall disease process. 
However, fibrosis markers could be valuable for monitoring 
therapeutic responses to fibroblast-targeting therapies in defined 
subcohorts of patients with ILD.
The detection of ILD in the context of multiorgan inflamma-
tion and fibrosis might represent a challenge. Thus, the perfor-
mance of our radiotracers should ideally have been evaluated in 
a second, multisystemic animal model, which better reflects the 
human situation in CTD-ILD. However, the available literature 
on PET/CT imaging provides substantial evidence that even in 
patients with CTD with multiorgan involvement, ILD can reli-
ably be diagnosed.58–65
In conclusion, both integrin αvβ3 and SSTR2 are intriguing 
candidates for the visualisation of specific molecular processes 
in ILD. Since SSTR2 targeting 68Ga-DOTA-NOC PET/CT is 
already available in clinical routine for the diagnosis of neuro-
endocrine tumours and several RGD-targeted PET tracers such 
as 68Ga-NOTA-RGD are in clinical trials,11 18 19 the findings of 
our study could be easily and rapidly transferred into clinical 
application for proof-of-concept studies in patients with ILD. 
This could represent the first step towards molecular patients’ 
stratification and thus precision medicine approaches in ILD.
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